BMY
The table below shows Bristol-Myers Squibb Company's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B |
| Cost of revenue | $13.94B | $13.97B | $10.69B | $10.14B | $9.94B | $11.77B |
| Gross profit | - | - | - | - | - | $30.75B |
| R&D | $9.95B | $11.16B | $9.30B | $9.51B | $10.20B | $10.05B |
Bristol-Myers Squibb Company reported annual revenue of $48.19B for fiscal year 2025. That is down 0.2% from $48.30B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $19.43B (FY 2016) to $48.19B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $7.27B |
| $8.41B |
| $7.77B |
| $7.81B |
| $7.69B |
| $7.66B |
| Operating income | - | - | - | - | - | - |
| Income tax | $2.27B | $554.00M | $400.00M | $1.37B | $1.08B | $2.12B |
| Net income | $7.05B | -$8.95B | $8.03B | $6.33B | $6.99B | -$9.02B |
| EPS (diluted) | $3.46 | -$4.41 | $3.86 | $2.95 | $3.12 | -$3.99 |